Genome profiling of ERBB2-amplified breast cancers

被引：0

作者：

Fabrice Sircoulomb

Ismahane Bekhouche

Pascal Finetti

José Adélaïde

Azza Ben Hamida

Julien Bonansea

Stéphane Raynaud

Charlène Innocenti

Emmanuelle Charafe-Jauffret

Carole Tarpin

Farhat Ben Ayed

Patrice Viens

Jocelyne Jacquemier

François Bertucci

Daniel Birnbaum

Max Chaffanet

机构：

[1] Institut Paoli-Calmettes,Marseille Cancer Research Center, UMR891 Inserm

[2] Department of Molecular Oncology,Department of BioPathology

[3] Institut Paoli-Calmettes,Department of Medical Oncology

[4] Institut Paoli-Calmettes,Department of Medical Oncology

[5] Université de la Méditerranée,undefined

[6] Salah Azaiz Institute,undefined

来源：

BMC Cancer | / 10卷

关键词：

Epidermal Growth Factor Receptor; Estrogen Receptor; Trastuzumab; Copy Number Gain; Copy Number Aberration;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers
Battaglin, F.
Xiu, J.
Baca, Y.
Shields, A. F.
Goldberg, R. M.
Puccini, A.
Tokunaga, R.
Arai, H.
Wang, J.
Kawanishi, N.
Seeber, A.
Astaturov, I.
Lockhart, A. C.
Zhang, W.
Marshall, J. L.
Korn, W. M.
Lenz, H. J.
ANNALS OF ONCOLOGY, 2020, 31 : S1100 - S1100
[32] Novel ERBB2 Variant Potentially Associated with Resistance against Anti-HER2 Monoclonal Antibody-Based Therapy in ERBB2-Amplified Metastatic Colorectal Cancer
Iida, Naoko
Imai, Mitsuho
Okamoto, Wataru
Kato, Takeshi
Esaki, Taito
Kato, Ken
Komatsu, Yoshito
Yuki, Satoshi
Masuishi, Toshiki
Nishina, Tomohiro
Ebi, Hiromichi
Taniguchi, Hiroya
Nonomura, Norio
Sunakawa, Yu
Shiozawa, Manabu
Yamazaki, Kentaro
Boku, Shogen
Bando, Hideaki
Shiraishi, Yuichi
Kobayashi, Maki
Goto, Hiroki
Sato, Akihiro
Fujii, Satoshi
Yoshino, Takayuki
Nakamura, Yoshiaki
CLINICAL CANCER RESEARCH, 2024, 30 (18) : 4167 - 4178
[33] Updated biomarker results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer.
Gomez, H. L.
Chavez, M. A.
Doval, D. C.
Nag, S.
Chow, L. W.
Chang, P. C.
Ahmad, N. M.
Berger, M.
Arbushites, M.
Westlund, R.
Stanislaus, M.
Zaks, T.
Stein, S.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S68 - S68
[34] Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases
Owen, Daniel R.
Wong, Hui-li
Bonakdar, Melika
Jones, Martin
Hughes, Christopher S.
Morin, Gregg B.
Jones, Steven J. M.
Renouf, Daniel J.
Lim, Howard
Laskin, Janessa
Marra, Marco
Yip, Stephen
Schaeffer, David F.
COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2018, 4 (02):
[35] A reason why the ERBB2 gene is amplified and not mutated in breast cancer
Birnbaum, Daniel
Sircoulomb, Fabrice
Imbert, Jean
CANCER CELL INTERNATIONAL, 2009, 9
[36] A reason why the ERBB2 gene is amplified and not mutated in breast cancer
Daniel Birnbaum
Fabrice Sircoulomb
Jean Imbert
Cancer Cell International, 9
[37] Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
Xia, WL
Bisi, J
Strum, J
Liu, LH
Carrick, K
Graham, KM
Treece, AL
Hardwicke, MA
Dush, M
Liao, QY
Westlund, RE
Zhao, SM
Bacus, S
Spector, NL
CANCER RESEARCH, 2006, 66 (03) : 1640 - 1647
[38] Chromatin Modifications Sequentially Enhance ErbB2 Expression in ErbB2-Positive Breast Cancers
Mungamuri, Sathish Kumar
Murk, William
Grumolato, Luca
Bernstein, Emily
Aaronson, Stuart A.
CELL REPORTS, 2013, 5 (02): : 302 - 313
[39] Molecular distinctions among ERBB2-overexpressing breast cancers
SS Jeffrey
Breast Cancer Research, 7
[40] C-ERBB-2 ACTIVITY IN SCREEN DETECTED BREAST CANCERS
DORIS, CP
ANDERSON, TJ
THOMPSON, AM
GULLICK, WJ
CHETTY, U
JOURNAL OF PATHOLOGY, 1991, 163 (02): : A179 - A179

← 1 2 3 4 5 →